

Prescription Monitoring Program Advisory Council State of Louisiana

October 12, 2022

MINUTES

A meeting of the Louisiana Prescription Monitoring Program (PMP) Advisory Council scheduled to meet on Wednesday, October 12, 2022 at the office of the Louisiana Board of Pharmacy, 3388 Brentwood Drive in Baton Rouge, Louisiana 70809, convened at 1:07 p.m. to consider the following:

A G E N D A

- 1. Call to Order**
- 2. Amendments to Council Roster**
- 3. Quorum Call**
- 4. Call for Additional Agenda Items & Adoption of Agenda**
- 5. Consideration of Draft Minutes from Previous Meeting – July 13, 2022**
- 6. Opportunity for Public Comment**
- 7. Review of Program Operations**
- 8. Review of Proposed Legislation**
- 9. New Agenda Items Added During Meeting**
- 10. Calendar Notes**
- 11. Adjourn**

Advisory Council Representatives/Designees present: Marty McKay (LABP) chaired the meeting. Also present were Mary Peyton (LSBME), Annette Droddy (LDA), Shelly Esnard (LAPA), Lawrence Alexander (DEA), Erin Conner (LSBD), Monique Calmes (LSBN), Lisa C. Bayhi (LANP), Jeff Gaude (NACDS), Chris Melancon (La. Senate-Chair H&W), Lauren Bailey (LSMS), Ricky T. Guidry (LIPA), and Crystal Carter (LPA).

Others present: Joe Fontenot, Carlos Finalet, Nerissa Montgomery, Reshmi Ravindranath, Carley Leach (all LABP), and Shelly Dupre (La. Alliance for Retail Pharmacies)

Amendments to Council Roster

Mr. McKay stated there has been amendments to the Council Roster due to the change in leadership since the last Council meeting. If a replacement member appointment form is needed, submit the form to the PMP office.

Call for Additional Agenda Items & Adoption of Agenda

No additional agenda items introduced; agenda adopted.

Consideration of Draft Minutes from July 13, 2022 Meeting

The July 13, 2022 meeting minutes was approved by consensus with no corrections.

Opportunity for Public Comment

No public comments.

Review of Program Operations

Joe Fontenot, Executive Director, presented statistical information regarding the program to the council.

(Attachment 1).

Mr. Fontenot explained there has been a continued decrease in the number of opioid and controlled dangerous substance prescriptions being dispensed and reported to the program. There has been a consistent, overall decrease in the number of controlled dangerous substance dispensations over time.

While addressing a question regarding how MAT drugs are incorporated into the overall opioid dispensation calculations, Mr. Fontenot explained how Bamboo Health's new software transition allows pharmacies reporting to the PMP to differentiate between MAT drugs used for opioid dependency treatment or other treatment types.

Additional grant funding has been provided by the LDH - Office of Public Health - Bureau of Community Preparedness. This funding will cover the licensing fees associated with Gateway© integration through December 31, 2023.

PMP Advisory Council Meeting Minutes

October 12, 2022

Page 2

Mr. Fontenot reported that both the AWA[®] and Gateway[®] searches have continued to increase each year with the greatest increase in the number of Gateway[®] searches due to integration efforts. Mr. Fontenot reported that the amount of law enforcement, prosecutorial, and specialty court PMP requests have somewhat decreased overtime.

Review of Proposed Legislation

Mr. Fontenot briefly reviewed the proposed draft legislation which would change the meeting frequency from quarterly to at least once annually and adds the exception for electronic meetings as detailed in the Legislative Proposal ~ PMP, Draft #1. Mr. McKay stated that any changes to the Statute 40:1005 will need to be brought to the Regulation Revision Committee and the Board has the final say before being brought before the legislature. Consensus was reached by members to bring the proposed legislation to the Board for approval. **(Attachment 2)**.

New Agenda Items Added During Meeting

No new agenda items added.

Calendar Notes

The Chair, Mr. Marty McKay, stated in accordance with the council's current preference for meeting dates, we have identified meeting dates for the Calendar Year 2023: January 11, April 12, July 12, and October 11.

Adjournment

With no business remaining, the council meeting was adjourned at 1:40 p.m.

I certify that the foregoing are true and accurate minutes.

Joe Fontenot
Executive Director
Louisiana Board of Pharmacy




LOUISIANA
BOARD of
PHARMACY

PRESCRIPTION MONITORING PROGRAM (PMP)

ADVISORY COUNCIL MEETING – OCTOBER 12, 2022


Number of Eligible Prescription Transactions Reported to the PMP

Reporting through 9/30/2022



PMP Reporting Comparisons - CDS


Reporting through 9/30/2022



3

PMP Reporting Comparisons - Opioids


Reporting through 9/30/2022



4

PMP Reporting Comparisons

Reporting through 9/30/2022



5


PMP User Stats for 2022Q3 (07/01/2022 - 09/30/2022)

PMP Healthcare Provider Role	Number of Providers Eligible for PMP Access (as of 09/30/2022)	Number of Providers with Active PMP Access Privileges (as of 09/30/2022)	Number of PMP Requests by Providers through AWARxE® During 2022Q3	Number of PMP Requests by Providers through Gateway® During 2022Q3
Physician (MD, DO)	13,503	9,508	512,074	4,660,712
Nurse Practitioner (APRN)	4,755	3,812	224,335	557,465
Dentist (DDS)	2,183	1,510	6,250	8,163
Physician Assistant (PA)	1,240	964	40,536	52,042
Optometrist (OD)	370	160	3	0
Podiatrist (DPM)	170	119	2,072	0
Medical Psychologist (MP)	96	92	10,216	6,432
Medical Intern/Resident	1,676	1,336	11,248	66,527
Prescriber's Delegate	N/A	3,699	195,834	0
Pharmacist (PST)	9,682	5,189	1,133,772	2,154,119
Pharmacist's Delegate	N/A	1,609	132,046	0
Totals	33,675	27,998	2,268,386	7,505,460

6

Louisiana Prescriber & Pharmacist Searches through AWAxE® and Gateway®

(Ending 9/30/2022)



7


PMP Interstate Data Sharing through PMP InterConnect®

As of September 30, 2022, the Louisiana PMP is sharing with 35 PMPs (1 federal district, 1 territory, 1 federal jurisdiction, and 32 states).

Alabama	Alaska	Arizona	Arkansas
Colorado	Connecticut	Delaware	D.C.
MHS-DOD	Florida	Georgia	Idaho
Indiana	Iowa	Kansas	Maine
Massachusetts	Michigan	Minnesota	Mississippi
Montana	Nevada	New Mexico	North Carolina
North Dakota	Oklahoma	Pennsylvania	Puerto Rico
Rhode Island	South Carolina	South Dakota	Tennessee
Texas	Virginia	West Virginia.	

8

Law Enforcement, Prosecutorial Officials, and Specialty Court PMP Requests



La. R.S. 40:1005. Prescription monitoring program advisory council

A. The advisory council shall consist of the following members, each of whom may appoint a designee:

- (1) The president of the Louisiana State Board of Medical Examiners.
- (2) The president of the Louisiana State Board of Dentistry.
- (3) The president of the Louisiana State Board of Nursing.
- (4) The president of the Louisiana State Board of Optometry Examiners.
- (5) Repealed by Acts 2013, No. 27, §2, eff. May 23, 2013.
- (6) The president of the Louisiana Academy of Physicians Assistants.
- (7) The president of the Louisiana Board of Pharmacy.
- (8) The superintendent of the Louisiana State Police.
- (9) The administrator of the United States Drug Enforcement Administration.
- (10) The speaker of the Louisiana House of Representatives.
- (11) The president of the Louisiana Senate.
- (12) The chairman of the House Committee on Health and Welfare.
- (13) The chairman of the Senate Committee on Health and Welfare.
- (14) The secretary of the Louisiana Department of Health.
- (15) The president of the Louisiana State Medical Society.
- (16) The president of the Louisiana Dental Association.
- (17) The president of the Louisiana Association of Nurse Practitioners.
- (18) The president of the Optometry Association of Louisiana.
- (19) The president of the Louisiana Pharmacists Association.
- (20) The president of the Louisiana Independent Pharmacies Association.
- (21) The president of the National Association of Chain Drug Stores.
- (22) The president of the Louisiana Sheriffs' Association.
- (23) The president of the Louisiana District Attorneys Association.
- (24) The president of the Pharmaceutical Research and Manufacturers of America.
- (25) The president of the Louisiana Academy of Medical Psychologists.
- (26) Repealed by Acts 2013, No. 27, §2, eff. May 23, 2013.

B. The members of the advisory council shall serve at the pleasure of their respective appointing authorities, eleven of whom shall constitute a quorum for the transaction of all business. The members shall elect a chairman and vice chairman whose duties shall be established by the advisory council. The board shall fix a time and place for regular meetings of the advisory council, which shall meet at least quarterly once annually. The advisory council shall establish policies and procedures necessary to carry out its duties.

C. Notwithstanding any other provision of law to the contrary, the advisory council may conduct and its members may attend and participate in a meeting via electronic means provided:

(1) No later than twenty-four hours prior to a meeting conducted pursuant to the provisions of this Section, the advisory council shall provide for all of the following:

a. The notice and agenda for the meeting, which shall be posted on the website of the Louisiana Board of Pharmacy, emailed to any member of the public or the news media who requests notice of meetings of the public body, and widely distributed to every known news media outlet that broadcasts or publishes news within the geographic area within the jurisdiction of the Louisiana Board of Pharmacy.

b. Detailed information regarding how members of the public may participate in the meeting and submit comments regarding matters on the agenda, which information shall be posted on the website of the Louisiana Board of Pharmacy, emailed to any member of the public or the news media who requests notice of meetings of the public body, and widely distributed to every known news media outlet that broadcasts or publishes news within the geographic area within the jurisdiction of the Louisiana Board of Pharmacy.

(2) For each meeting conducted pursuant to this Section:

a. The advisory council shall provide a mechanism to receive public comment electronically both prior to and during the meeting.

b. The advisory council shall properly identify and acknowledge all public comments during the meeting and shall maintain those comments in its record of the meeting.

c. The presiding officer of the advisory council shall ensure that each person participating in the meeting is properly identified.

d. The presiding officer shall ensure that all parts of the meeting, excluding any matter discussed in executive session, are clear and audible to all participants in the meeting including the public.

(3) For the purposes of this Section, the following words and phrases shall have the following meanings:

a. "Meeting via electronic means" shall mean a meeting occurring via teleconference or video conference.

b. "Teleconference" shall mean a method of communication which enables persons in different locations to participate in a meeting and to hear and otherwise communicate with each other.

c. "Video conference" shall mean a method of communication which enables persons in different locations to participate in a meeting and to see, hear, and otherwise communicate with each other.

~~€. D.~~ The board shall seek, and the advisory council shall provide, information and advice regarding the development and operation of the electronic monitoring system, including but not limited to the following:

(1) Which controlled substances should be monitored.

(2) Which drugs of concern demonstrate a potential for abuse and should be monitored.

(3) Design and implementation of educational courses identified in R.S. 40:1008.

(4) The methodology to be used for analysis and interpretation of prescription monitoring information.

(5) Design and implementation of a program evaluation component.

(6) Identification of potential additional members to the advisory council.

Acts 2006, No. 676, §1, eff. July 1, 2006; Acts 2010, No. 142, §1; Acts 2010, No. 144, §1; Acts 2013, No. 27, §2, eff. May 23, 2013; Acts 2018, No. 206, §4.